secwatch.observer — SEC 8-K summary
======================================

Issuer:     Glucotrack, Inc. (GCTK)
CIK:        0001506983
Form:       8-K
Filed at:   2026-09-23T13:21:42+00:00
Accession:  0001493152-26-043844
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Glucotrack (Lōkahi) advances LT-100, submits protocol; ai² platform flags 45 assets
--------------------------------------------------------------------------------

- Completed strategic business combination on July 14, 2026; Glucotrack Technologies now wholly owned subsidiary.
- LT-100 for osteoarthritis knee pain: clinical protocol submitted for regulatory review; targeting near-term study start.
- Planned study evaluates once-weekly subcutaneous injection vs historical 15 weekly intradermal injections.
- ai² platform has 14 university partners, screening 12,000+ abandoned late-stage programs; 45 assets met initial criteria.
- Qare first ai² Accelerator initiative; business model aims to monetize assets before registration trials.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1506983/000149315226043844/0001493152-26-043844-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1506983/000149315226043844/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-043844

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer